Publications by authors named "M Richardet"
Article Synopsis
- The evolving oncology treatment landscape shows a need for better administration options that enhance patient experiences and healthcare efficiency.
- A phase III trial (CheckMate 67T) compared subcutaneous nivolumab to intravenous nivolumab in patients with advanced clear cell renal cell carcinoma, focusing on pharmacokinetics and objective response rates.
- Results indicated that subcutaneous nivolumab was noninferior to the intravenous form, showing similar efficacy and safety profiles, with no new safety concerns emerging.
Article Synopsis
- Checkpoint inhibitor therapy, particularly nivolumab combined with ipilimumab, shows promise for patients with high tumor mutational burden (TMB-H) across various tumor types, indicating a potential survival benefit.
- The study involved 201 patients with advanced solid tumors who were resistant to standard treatments; they were randomly assigned to receive either the combination of nivolumab and ipilimumab or nivolumab alone, with the effectiveness measured based on objective response rates.
- Results demonstrated higher response rates in patients with TMB-H tumors who received the combination therapy, and the safety profile was acceptable, suggesting this treatment could be beneficial for patients with limited options.
Background: Nivolumab plus cabozantinib (NIVO + CABO) was approved for first-line treatment of advanced renal cell carcinoma (aRCC) based on superiority versus sunitinib (SUN) in the phase III CheckMate 9ER trial (18.1 months median survival follow-up per database lock date); efficacy benefit was maintained with an extended 32.9 months of median survival follow-up.
View Article and Find Full Text PDFBackground: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) are usually asymptomatic and seek treatments that improve survival but have a low risk of adverse events. Darolutamide, a structurally distinct androgen receptor inhibitor (ARi), significantly reduced the risk of metastasis and death versus placebo in ARAMIS. We assessed the extended safety and tolerability of darolutamide and the time-course profile of treatment-emergent adverse events (TEAEs) related to ARis and androgen-suppressive treatment.
View Article and Find Full Text PDFThe economic evaluation of mastitis control is challenging. The objective of this study was to perform the economic evaluation of mastitis control, under different intervention scenarios, quantifying the total cost of mastitis caused by in Holstein cows in Argentina. A model was set for a dairy herd of Holstein cows endemically infected with .
View Article and Find Full Text PDF